Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
Rapid card test kits for iScreen malaria card antigen (Pf/Pv) & iScreen dengue NS1
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
Supply readiness follows months of manufacturing to ensure timely and ample supply
UTD2 is the world's first oral epothilone microtubule inhibitor
Subscribe To Our Newsletter & Stay Updated
